The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...

February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart biosimilar. February brought policy updates and several biosimilar approvals, ...

Voter information pamphlets are on their way to over 376,000 registered voters in the County of San Diego’s First Supervisorial District for the April 8 special primary election. The Registrar’s ...

The Brian Dempsey Memorial Pamphlet Prize, now a biennial competition, is open for entries from writers in the UK. Entries can be on any subject. Poems eligible to be entered should be unpublished ...

The Global Oncology Biosimilars Market is expected to grow at 18.5% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for ...

Consistent with its mission of delivering affordability without compromising access, MedImpact’s approach to biosimilars is pharmacy- and manufacturer-neutral. “Stelara has long been a cornerstone ...

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...

(Reuters) - Johnson & Johnson (NYSE:JNJ) sued Samsung (KS:005930) Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis ...

The large share of this segment can be owing to the growth in biologics and biosimilar manufacturing. Additionally, increasing number of biopharmaceuticals receiving regulatory approvals for ...

Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals (NYSE:TEVA) said on Tuesday that the U.S. FDA has accepted for review a Biologics License Application for a biosimilar targeting Regeneron’s (REGN ...